Sun Pharmaceutical Industries rose 0.97% to Rs 643.80 at 9:25 IST on BSE after the company announced successful phase 3 confirmatory clinical trial results for Seciera, for the treatment of dry eye disease.
The announcement was made after market hours yesterday, 4 January 2017.Meanwhile, the BSE Sensex was up 136.38 points, or 0.51%, to 26,769.51.
On the BSE, so far 15,731 shares were traded in the counter, compared with average daily volumes of 5.34 lakh shares in the past one quarter. The stock had hit a high of Rs 646.25 and a low of Rs 642 so far during the day.
Sun Pharmaceutical Industries announced successful phase 3 confirmatory clinical trial results for Seciera (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. Seciera is a patented, novel, proprietary nanomicellar formulation of cyclosporine A 0.09%.
It is a clear, preservative-free, aqueous solution. Seciera is being developed by Ocular Technologies, a company recently acquired by Sun Pharma. Following this acquisition, Sun Pharma owns exclusive, worldwide rights to Secier and is developing it to commercialize for global markets including US, Europe, and Japan, as well as several emerging markets.
On a consolidated basis, Sun Pharmaceutical Industries' net profit rose 90.2% to Rs 2471.11 crore on 13.2% growth in net sales to Rs 7764.03 crore in Q2 September 2016 over Q2 September 2015.
Sun Pharmaceutical Industries is amongst the largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
